The question now for Biogen is whether that difference is sufficiently compelling to encourage patients to switch from Tecfidera, or to start with Vumerity rather than one of its rival therapies.

with the switch group showing a more modest result that was still better than the no-treatment arm. According to Eisai and Biogen, that level of change on the CDR-SB can be "the difference between ...

A higher dose of Spinraza may be more effective than the currently approved dosing schedule for maintaining motor function in ...

VJ received conference travel support from Merck and Roche and speaker’s honoraria from Biogen and Roche outside of the submitted work. She receives research support from the Australian National ...

Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...

Woot's back with a Spring Sale that features some excellent Switch game deals. From Super Mario RPG to Sonic X Shadow Generations to Princess Peach: Showtime, there are so many options on sale ...

We're rounding up all the best Nintendo Switch bundle deals available right now to help you save cash on your next console Nintendo Switch bundles are continuing to look strong this week ...

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.

But on the flip side, how quickly do you let patients go on the same treatment before you feel like you need to switch, or you need to do something different? Rovin: Yeah, both KDIGO and the ACR ...

Over my forty years or so in and around dealing rooms and financial markets, I have heard many theories as to how to approach that problem and have settled on a process that has worked for me ...